Pivotal bioVenture Partners Investment Advisor LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 13, 2026, for the 2025 Q4 period, Pivotal bioVenture Partners Investment Advisor LLC held in its portfolio 12 assets valued at $258,658,319 (i.e. $258.66M).

The most valuable assets in the portfolio included: VAXCYTE INC ($63.32M), OCULIS HOLDING AG ($45.71M), and ARCUTIS BIOTHERAPEUTICS INC ($39.69M).

The chart below shows the top 10 valuable assets, and the table below shows the top 12 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Pivotal bioVenture Partners Investment Advisor LLC Portfolio

VAXCYTE INC

OCULIS HOLDING AG

ARCUTIS BIOTHERAPEUTICS INC

EVOMMUNE INC

ZENAS BIOPHARMA INC

TREVI THERAPEUTICS INC

IMMUNOME INC

MAPLIGHT THERAPEUTICS INC

BIOAGE LABS INC

RECURSION PHARMACEUTICALS IN

Pivotal bioVenture Partners Investment Advisor LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
VAXCYTE INC	1372425	63323690	COM
OCULIS HOLDING AG	2288658	45704500	ORDINARY SHARES
ARCUTIS BIOTHERAPEUTICS INC	1366624	39686761	COM
EVOMMUNE INC	1926943	32989264	COM SHS
ZENAS BIOPHARMA INC	591991	21495193	COM
TREVI THERAPEUTICS INC	1256782	15734911	COM
IMMUNOME INC	732512	15734358	COM
MAPLIGHT THERAPEUTICS INC	611447	10743124	COM
BIOAGE LABS INC	653374	8644138	COM
RECURSION PHARMACEUTICALS IN	595518	2435669	CL A
RALLYBIO CORP	2404644	1649586	COM
BOLT BIOTHERAPEUTICS INC	94573	517125	COM NEW